Advertisement
U.S. markets closed
  • S&P 500

    5,130.95
    -6.13 (-0.12%)
     
  • Dow 30

    38,989.83
    -97.57 (-0.25%)
     
  • Nasdaq

    16,207.51
    -67.39 (-0.41%)
     
  • Russell 2000

    2,074.31
    -2.08 (-0.10%)
     
  • Crude Oil

    78.62
    -0.12 (-0.15%)
     
  • Gold

    2,122.60
    -3.70 (-0.17%)
     
  • Silver

    24.10
    +0.11 (+0.48%)
     
  • EUR/USD

    1.0855
    -0.0004 (-0.03%)
     
  • 10-Yr Bond

    4.2190
    +0.0390 (+0.93%)
     
  • GBP/USD

    1.2693
    -0.0000 (-0.00%)
     
  • USD/JPY

    150.4640
    +0.0360 (+0.02%)
     
  • Bitcoin USD

    67,918.19
    +3,939.37 (+6.16%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,640.33
    -42.17 (-0.55%)
     
  • Nikkei 225

    40,030.39
    +119.59 (+0.30%)
     

Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs

Lexaria Bioscience Corp.
Lexaria Bioscience Corp.

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via InvestorWireLexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands within the Dynamic Brand Portfolio @ IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

To view the full publication, “Can Diabetes, Weight-Loss Drugs Get Even Better?”,
please visit: https://nnw.fm/q9osg

The prestigious “New England Journal of Medicine” recently published results of a large study of 2,539 adults wherein weight loss of 49 to 52 pounds was a common outcome. With more than 37 million Americans suffering from diabetes, and with obesity at epidemic levels, it’s little wonder that millions of people are singing their praises of the new class of drugs responsible for these outrageously positive outcomes. GLP-1 agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with type 2 diabetes but are also helping treat obesity. Seems everyone is excited about controlling blood sugar and easily losing weight.

But there may be an even better avenue to increased effectiveness and better outcomes. Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug-delivery platforms, began diabetes-related formal studies last year with its DehydraTECH(TM) platform, which showed reduced blood-sugar levels and lowered body weight. With such encouraging early results, Lexaria is planning to launch new human and animal studies to examine whether DehydraTECH processing can make GLP-1 drugs such as semaglutide even better.

About Lexaria Bioscience Corp.

Lexaria’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 37 patents granted and many patents pending worldwide.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: https://www.NetworkNewsWire.com/Disclaimer

NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is powered by IBN


Advertisement